Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Monoclonal antibodies blocking CGRP for prevention of migraine
  • Home
  • /
  • Monoclonal antibodies blocking CGRP for prevention of migraine
  1. Home /
  2. Archives /
  3. Vol. 18 No. 1 (2023) /
  4. Articles

Monoclonal antibodies blocking CGRP for prevention of migraine

Authors

  • Alicja Maziarczyk Student, Wydział Lekarski, Uniwersytet Medyczny w Lublinie https://orcid.org/0009-0001-6634-4215
  • Dominika Miazga Student, Wydział Lekarski, Uniwersytet Medyczny w Lublinie https://orcid.org/0000-0001-8715-9142
  • Laura Surdacka Student, Wydział Lekarski, Uniwersytet Medyczny w Lublinie https://orcid.org/0009-0006-3439-4003

DOI:

https://doi.org/10.12775/JEHS.2023.18.01.005

Keywords

CGRP, monoclonal antibody, migraine, prevention

Abstract

Introduction and purpose

Monoclonal antibodies blocking calcitonin gene-related peptide (CGRP) are a novel treatment strategy developed specifically for prevention of migraine. Four drugs belong to this group: eptinezumab, fremanezumab and galcanezumab, which bind to the peptide; and erenumab, which blocks the CGRP receptor. CGRP is involved in nociception and plays a crucial role in the pathophysiology of migraine, as it is released in the trigeminal ganglion as a response to local cerebral vasoconstriction in order to cause dilation of the vessels and maintain cerebral blood flow. Moreover, administration of CGRP, especially among migraineurs, induces a migraine-type headache. The aim of the paper is to discuss the potential of monoclonal antibodies blocking CGRP for the prevention of migraine and to outline their safety and efficacy profile.

State of knowledge

Several randomised clinical trials have shown a significant efficacy of these drugs compared to placebo in reducing monthly migraine affected days, among patients suffering from both episodic and chronic migraine. Incidence rate of side effects is low; the most common were mild to moderate (e.g. pain at the injection site, upper respiratory tract infections, nasopharyngitis, back pain and urinary tract infection). Anti-CGRP monoclonal antibodies exhibit a superior benefit-to-risk ratio than established preventive treatments.

Conclusions

Randomized controlled trials are still needed in order to compare different anti-CGRP monoclonal antibodies and asses their long-term safety profile. In conclusion, these drugs seem to provide promising prospects of improving the lives of migraineurs. As based on current knowledge, the benefits are superior to the likelihood of harm.

References

Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019 May;59(5):659-681. doi: 10.1111/head.13529. Epub 2019 Apr 14. PMID: 30982963; PMCID: PMC6593989.

Lucas C. Migraine with aura. Rev Neurol (Paris). 2021 Sep;177(7):779-784. doi: 10.1016/j.neurol.2021.07.010. Epub 2021 Aug 9. PMID: 34384631.

R P, S C N, S H, K R. Migraine Disability, Quality of Life, and Its Predictors. Ann Neurosci. 2020 Jan;27(1):18-23. doi: 10.1177/0972753120929563. Epub 2020 Jul 3. PMID: 32982095; PMCID: PMC7499825.

Edvinsson L. CGRP and migraine: from bench to bedside. Rev Neurol (Paris). 2021 Sep;177(7):785-790. doi: 10.1016/j.neurol.2021.06.003. Epub 2021 Jul 15. PMID: 34275653.

Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34. PMID: 30681821.

Rammohan K, Mundayadan SM, Das S, Shaji CV. Migraine and Mood Disorders: Prevalence, Clinical Correlations and Disability. J Neurosci Rural Pract. 2019 Jan-Mar;10(1):28-33. doi: 10.4103/jnrp.jnrp_146_18. PMID: 30765967; PMCID: PMC6337984.

Edvinsson L. Role of CGRP in Migraine. Handb Exp Pharmacol. 2019;255:121-130. doi: 10.1007/164_2018_201. PMID: 30725283.

Silberstein SD. Topiramate in Migraine Prevention: A 2016 Perspective. Headache. 2017 Jan;57(1):165-178. doi: 10.1111/head.12997. Epub 2016 Nov 30. PMID: 27902848.

Ha H, Gonzalez A. Migraine Headache Prophylaxis. Am Fam Physician. 2019 Jan 1;99(1):17-24. PMID: 30600979.

Rivera-Mancilla E, Villalón CM, MaassenVanDenBrink A. CGRP inhibitors for migraine prophylaxis: a safety review. Expert Opin Drug Saf. 2020 Oct;19(10):1237-1250. doi: 10.1080/14740338.2020.1811229. Epub 2020 Sep 21. PMID: 32811190.

Szkutnik-Fiedler D. Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics. 2020 Dec 3;12(12):1180. doi: 10.3390/pharmaceutics12121180. PMID: 33287305; PMCID: PMC7761673.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 May;38(6):1026-1037. doi: 10.1177/0333102418759786. Epub 2018 Feb 22. PMID: 29471679.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. 2020 Aug 4;95(5):e469-e479. doi: 10.1212/WNL.0000000000010019. Epub 2020 Jul 7. PMID: 32636324; PMCID: PMC7455346.

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28. PMID: 28460892.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853. PMID: 29800211; PMCID: PMC6583237.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038. PMID: 29171818.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018 Sep 1;75(9):1080-1088. doi: 10.1001/jamaneurol.2018.1212. Erratum in: JAMA Neurol. 2019 Jul 1;76(7):872. PMID: 29813147; PMCID: PMC6143119.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16. PMID: 30446596; PMCID: PMC6329331.

Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020 Mar;40(3):241-254. doi: 10.1177/0333102420905132. Epub 2020 Feb 19. PMID: 32075406; PMCID: PMC7066477.

Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020 Mar 31;94(13):e1365-e1377. doi: 10.1212/WNL.0000000000009169. Epub 2020 Mar 24. PMID: 32209650; PMCID: PMC7274916.

Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, Vigneri S, Edvinsson L, Maassen Van Den Brink A; European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017 Sep 25;18(1):96. doi: 10.1186/s10194-017-0807-1. PMID: 28948500; PMCID: PMC5612904.

Downloads

  • PDF

Published

2023-04-03

How to Cite

1.
MAZIARCZYK, Alicja, MIAZGA, Dominika and SURDACKA, Laura. Monoclonal antibodies blocking CGRP for prevention of migraine. Journal of Education, Health and Sport. Online. 3 April 2023. Vol. 18, no. 1, pp. 43-48. [Accessed 17 May 2025]. DOI 10.12775/JEHS.2023.18.01.005.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 18 No. 1 (2023)

Section

Articles

License

Copyright (c) 2023 Alicja Maziarczyk, Dominika Miazga, Laura Surdacka

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 385
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

CGRP, monoclonal antibody, migraine, prevention
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop